Bactericidal effects of polyhexamethylene biguanide against intracellular Staphylococcus aureus EMRSA-15 and USA 300

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 5, 2016, Pages 1252-1259

  Kamaruzzaman, Nor Fadhilah ^a,b   Firdessa, Rebuma ^c   Good, Liam ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b UNIVERSITI MALAYSIA KELANTAN   (Malaysia)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; FUSIDIC ACID; GENTAMICIN; NADIFLOXACIN; POLY(HEXAMETHYLENEBIGUANIDE); ANTIINFECTIVE AGENT; BIGUANIDE DERIVATIVE; POLIHEXANIDE; QUINOLIZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DRUG UPTAKE; EUKARYOTIC CELL; EXOCYTOSIS; INTRACELLULAR KILLING; KERATINOCYTE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; RESAZURIN ASSAY; STAPHYLOCOCCUS AUREUS; CELL LINE; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BIGUANIDES; CELL LINE; FLUOROQUINOLONES; HUMANS; KERATINOCYTES; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; QUINOLIZINES; STAPHYLOCOCCUS AUREUS;

EID: 84965022457     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv474     Document Type: Article

References (39)

1. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65: 35-44.
2. Grice E, Segre J. The skin microbiome. Nat Rev Microbiol 2013; 9: 244-53.
3. Singer AJ, Talan DA. Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus. N Engl J Med 2014; 370: 1039-47.
4. Garzoni C, Kelley WL. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol 2009; 17: 59-65.
5. Lehar SM, Pillow T, Xu M et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 2015; 527: 323-8.
6. Soong G, Chun J, Parker D et al. Staphylococcus aureus activation of caspase 1/calpain signaling mediates invasion through human keratinocytes. J Infect Dis 2012; 205: 1571-9.
7. Johnson AP, Aucken HM, Cavendish S et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 2001; 48: 143-4.
8. Moore P, Lindsay J. Molecular characterisation of the dominant UK methicillin-resistant Staphylococcus aureus strains, EMRSA-15 and EMRSA-16. Epidemiol Antimicrob Resist 2002; 51: 516-21.
9. Wolter DJ, Chatterjee A, Varman M et al. Isolation and characterization of an epidemic methicillin-resistant Staphylococcus aureus 15 variant in the central United States. J Clin Microbiol 2008; 46: 3548-9.
10. Holden M, Hsu L, Kurt K et al. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res 2013; 23: 653-64.
11. King MD, Humphrey BJ, Wang YF et al. Emergence of communityacquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144: 309-17.
12. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother 2009; 64: 441-6.
13. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: 18-55.
14. Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 2009; 49: 1541-9.
15. Patel JB, Gorwitz RJ, Jernigan J. Mupirocin resistance. Clin Infect Dis 2009; 49: 935-41.
16. Nenoff P, Haustein U, Hitte N. Activity of nadifloxacin (opc-7251) and seven other antimicrobial agents against aerobic and anerobic Grampositive bacteria isolated from bacterial skin infections. Chemotherapy 2003; 50: 196-201.
17. Alba V, Urban E, Angeles DominguezMet al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possible evolution of resistance after 2 years of use in Germany. Int J Antimicrob Agents 2009; 33: 272-5.
18. Narayanan V, Motlekar S, Kadhe G et al. Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies. Dermatol Ther (Heidelb) 2014; 4: 233-48.
19. Gilbert P, Moore LE. Cationic antiseptics: diversity of action under a common epithet. J Appl Microbiol 2005; 99: 703-15.
20. Koburger T, Hubner N-O, Braun M et al. Standardised comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 2010; 65: 1712-9.
21. Messick CR, Pendland SL, Moshirfar M et al. In vitro activity of polyhexamethylene biguanide (PHMB) against fungal isolates associated with infective keratitis. J Antimicrob Chemother 1999; 44: 291-302.
22. Hiti K. Viability of Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two hydrogen peroxide systems. Br J Ophthalmol 2002; 86: 144-6.
23. Romanowski EG, Yates KA, Connor K et al. The evaluation of polyhexamethylene biguanide (PHMB) as a disinfectant for adenovirus. JAMA Opthalmology 2013; 131: 495-8.
24. Gilliver S. PHMB: a well-tolerated antiseptic with no reported toxic effects. J Wound Care 2009; 10-3.
25. Kaehn K. Polihexanide: a safe and highly effective biocide. Skin Pharmacol Physiol 2010; 23: 7-16.
26. Butcher M. PHMB: an effective antimicrobial in wound bioburden management. Infection 2012; 21: 17-9.
27. Moore K, Gray D. Using PHMB antimicrobial to prevent wound infection. Wounds 2007; 3: 96-102.
28. Firdessa R, Good L, Amstaldam MC et al. Pathogen-and host-directed antileishmanial effects mediated by polyhexanide (PHMB). PLoS Negl Trop Dis 2015; 9: e0004041.
29. Nekhotiaeva N, Awasthi SK, Nielsen PE et al. Inhibition of Staphylococcus aureus gene expression and growth using antisense peptide nucleic acids. Mol Ther 2004; 10: 652-9.
30. Goh S, Loeffler A, Lloyd DH et al. Oxacillin sensitisation of methicillinresistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius by antisense peptide nucleic acids in vitro. BMC Microbiol 2015; 15: 2-10.
31. Otter JA, Havill NL, Boyce JM et al. Comparison of communityassociated methicillin-resistant Staphylococcus aureus from teaching hospitals in London and the USA, 2004-2006: where is USA300 in the UK? Eur J Clin Microbiol Infect Dis 2009; 28: 835-9.
32. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI. Wayne, PA, USA, 2007.
33. Edwards AM, Massey RC. Invasion of human cells by a bacterial pathogen. J Vis Exp 2011; 49: 1-4.
34. Vaudaux P, Waldvogel FA. Gentamicin antibacterial activity in the presence of human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1979; 16: 743-9.
35. Di Grazia A, Luca V, Segev-Zarko LA et al. Temporins A and B stimulate migration of HaCaT keratinocytes and kill intracellular Staphylococcus aureus. Antimicrob Agents Chemother 2014; 58: 2520-7.
36. Kirchhause T, Macia E, Pelish HE. Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol 2008; 438: 77-93.
37. Van Bambeke F, Michot J, Van Eldere J et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11: 256-80.
38. De Paula GF, Netto GI, Mattoso LH. Physical and chemical characterization of poly(hexamethylene biguanide) hydrochloride. Polymers (Basel) 2011; 3: 928-41.
39. Fraunholz M, Sinha B. Intracellular Staphylococcus aureus: live-in and let die. Front Cell Infect Microbiol 2012; 2: 43.